Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 4/20 | 0.55 |
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5762625 | 0.87 | GAA (0.54) | PPARDPPARAMCHR1LTA4HALDH1A1 | |
| SCHEMBL3862821 | 0.83 | PPARD (0.72) | PPARDPPARAPPARG | |
| SCHEMBL2006359 | 0.79 | PPARD (0.58) | PPARDPPARARAB9ANPC1PPARG | |
| SCHEMBL6385516 | 0.77 | ITGB3 (0.60) | PPARDPPARARAB9ANPC1 | |
| SCHEMBL3872672 | 0.77 | PPARA (0.54) | PPARDPPARALTA4HNTSR1PPARG | |
| SCHEMBL4824100 | 0.76 | PTPN1 (0.45) | PPARDPPARALTA4HNTSR1 | |
| SCHEMBL30395677 | 0.75 | PPARD (0.56) | PPARDPPARARAB9ANPC1PPARG | |
| SCHEMBL4478676 | 0.75 | PPARD (0.56) | PPARDPPARARAB9ANPC1PPARG | |
| SCHEMBL27587634 | 0.75 | BCL2 (0.56) | PPARDPPARA | |
| SCHEMBL2828419 | 0.74 | FFAR1 (0.63) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006525365-A | — | — | 2006-11-09 | — | — | JP | claimed |
| EP-1620422-A2 | PHENYL SUBSTITUTED CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | The Institutes for Pharmaceutical Discovery, LLC (US) | 2006-02-01 | — | — | EP | claimed |
| US-20050004369-A1 | Phenyl substituted carboxylic acids | INSTITUTES FOR PHARMACEUTICAL DISCOVERY, L.L.C. | 2005-01-06 | — | — | US | claimed |
| WO-2004099170-A2 | PHENYL SUBSTITUTED CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-11-18 | — | — | WO | claimed |
| US-7524878-B2 | Phenyl substituted carboxylic acids | THE INSTITUTE FOR PHARMACEUTICALS DISCOVERY LLC (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524878-B2 | Phenyl substituted carboxylic acids | THE INSTITUTE FOR PHARMACEUTICALS DISCOVERY LLC (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524878-B2 | Phenyl substituted carboxylic acids | THE INSTITUTE FOR PHARMACEUTICALS DISCOVERY LLC (US) | 2009-04-28 | — | — | US | disclosed |
| US-20050004369-A1 | Phenyl substituted carboxylic acids | INSTITUTES FOR PHARMACEUTICAL DISCOVERY, L.L.C. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004369-A1 | Phenyl substituted carboxylic acids | PTPA, PTPRS, PTPRO | PPARD 412/4885PPARA 134/4885MCHR1 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.